| Third-line sunitinib following sequential use of cytokine therapy and ... - UroToday |
|
|
UroToday BACKGROUND: The aim of this study was to evaluate the use of sunitinib as third-line therapy for metastatic renal cell carcinoma (mRCC). METHODS: This study included a total of 35 consecutive Japanese patients with mRCC who were treated with third-line |